Clinical trials
Completed Macular Edema trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
271 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 3 |
| 2002 | 3 |
| 2003 | 6 |
| 2004 | 8 |
| 2005 | 6 |
| 2006 | 14 |
| 2007 | 17 |
| 2008 | 12 |
| 2009 | 12 |
| 2010 | 11 |
| 2011 | 29 |
| 2012 | 23 |
| 2013 | 21 |
| 2014 | 16 |
| 2015 | 14 |
| 2016 | 16 |
| 2017 | 4 |
| 2018 | 8 |
| 2019 | 9 |
| 2020 | 7 |
| 2021 | 11 |
| 2022 | 2 |
| 2023 | 7 |
| 2024 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 271 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 23 |
| Allergan | 22 |
| National Eye Institute (NEI) | 20 |
| Bayer | 11 |
| Genentech, Inc. | 7 |
| Medical University of Vienna | 6 |
| Hospital Juarez de Mexico | 5 |
| Queen's University | 4 |
| Alcon Research | 3 |
| Clearside Biomedical, Inc. | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Macular Edema | 271 |
| Retinal Vein Occlusion | 84 |
| Diabetic Retinopathy | 48 |
| Diabetes Mellitus | 33 |
| Macular Degeneration | 25 |
| Retinal Diseases | 22 |
| Uveitis | 22 |
| Vision Disorders | 21 |
| Cataract | 15 |
| Choroidal Neovascularization | 7 |
Trials
Showing 1 to 25 of 271. Each trial links to its page on Pharma Observatory.
171 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.